ucsf life sciences week 1 diagnostics
TRANSCRIPT
![Page 1: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/1.jpg)
1
Diagnostics Cohort Week 1
UCSF Lean LaunchPad For Life SciencesOctober 1, 2013
Todd Morrill
![Page 2: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/2.jpg)
2
Cohort D-1: LLP-LSdx
• What are we talking about?
• What are we doing here?
• Who are we?
• Why bother?
![Page 3: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/3.jpg)
3
What is a diagnostic?
What we used to think:
Product which attempts to classify of an individual's condition into separate and distinct categories that allow medical decisions about treatment and prognosis to be made.
![Page 4: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/4.jpg)
4
What is a diagnostic?
What we used to think:
Product which attempts to classify of an individual's condition into separate and distinct categories that allow medical decisions about treatment and prognosis to be made.
![Page 5: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/5.jpg)
5
What is a diagnostic?
What we now think:
Product which attempts to classify of an individual's condition into separate and distinct categories that allow medical decisions about treatment and prognosis to be made.
Product, service, process, data setIndividual, group, population…Medical, nutritional, genetic, social…Decisions, information…Treatment, status, history, future, behavior…Prognosis, history, potential…
![Page 6: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/6.jpg)
6
What changed?
• Biology (knowledge and understanding of human and other bio/medical systems)
• Technology (PCR, mass spec, TEM, antibodies, PET)
• Population – Aging, richer
![Page 7: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/7.jpg)
7
What changed?
• Biology (knowledge and understanding of human and other bio/medical systems)
• Technology (PCR, mass spec, TEM, antibodies, PET)
• Population – Aging, richer, risk averse, and less pizza, dude
![Page 8: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/8.jpg)
8
What changed?
• Biology (knowledge and understanding of human and other bio/medical systems)
• Technology (PCR, mass spec, TEM, antibodies, PET)
• Population – Aging, richer, risk averse, and less pizza, dude
![Page 9: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/9.jpg)
9
And the industry is changing too
![Page 10: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/10.jpg)
10
So what…?So: Value Propositions are Complex
• Testing is more varied, complex and generally available than 20 years ago, for example:– Detection / Change (progression) / Stratification / Prediction /
Predilection– Lab, home brew, RUO, POC, consumer, pet, vet, food etc.– Sensitivity can exceed understanding of meaning– Odd value propositions in some markets: “Diagnosis” vs
“cleanliness” uses
• Medical, industrial, consumer, behavioral etc.• Tests vs Dx: stratification, status, content, etc.• In vivo vs. in vitro testing• Companion diagnostics, biomarker sets, genetic profiling
and unicorns
![Page 11: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/11.jpg)
11
So what…? So: Business Models are changing
• Roche• Siemens• Danaher• Abbott• ThermoFisher• Becton Dickinson• Johnson & Johnson• Alere• Sysmex• bioMerieux• Bio-Rad
• Idexx• Digene/Qiagen• Genomic Health• OraSure• Myriad Genetics• GE• Hologic• Complete Genomics• Illumina• Asuragen• Sequenom
Largest Dx Companies Smaller Dx Companies
PLATFORM EXECUTORS TECHNOLOGY INNOVATORS
![Page 12: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/12.jpg)
12
Executors
Large marketsRoutine analysesInternational scopeLarge distribution networksManufacturing excellenceEstablished platforms
Niche marketsComplex analysesFocused salesTechnology superiorityNovel platforms
?
EntrepreneurialAgileNicheInnovative……beyond technology
Technologists Innovators
![Page 13: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/13.jpg)
13
Who is Todd and why is he here?NSF National Program Faculty
• In vitro diagnostic tests (Bio-Rad Labs $1.3B Dx development, manufacturing, vendor)– Human, animal, food
• In vivo diagnostic discovery (Oxford GlycoSciences)• Biopharma discovery (Trellis, Lilly, Baxter, Pfizer)• Research tools (Novex, Bio-Rad, IO Informatics)• What’s fun?
– New technology discovery and development– Entrepreneurship: 3 startups
• NSF I-CorpsTM National Faculty. Instructor at Berkeley and UCSF .
![Page 14: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/14.jpg)
14
Steve mentioned this…
![Page 15: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/15.jpg)
15
Do Diagnostics fit into the BMC?(or how don’t they fit?)
![Page 16: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/16.jpg)
16
REGULATION
CLINICAL TRIALS
IP
REIMBURSEMENT
![Page 17: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/17.jpg)
17
REGULATION
CLINICAL TRIALS
IP
REIMBURSEMENT
![Page 18: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/18.jpg)
18
How we will fit DX into the BMC
REGULATION
CLINICAL TRIALS
IPREIMBURSEMENT
![Page 19: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/19.jpg)
19
How we will fit DX into the BMC
REGULATION
CLINICAL TRIALS
IPREIMBURSEMENT
![Page 20: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/20.jpg)
20
TAM / SAM / SOM
• Established tests – Use the current market size• Novel tests – Use current estimated need
• Population is IMPORTANT but money (revenue) is CRITICAL– Always state your markets in dollars– Use current markets, population, etc.– OK to note market growth if it is exceptional
![Page 21: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/21.jpg)
21
The importance of timing
“Ahead of his time”
![Page 22: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/22.jpg)
22
What we wish about healthcare
![Page 23: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/23.jpg)
23
What we have in healthcare: multisided markets
![Page 24: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/24.jpg)
24
What we have in healthcare: complex processes
![Page 25: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/25.jpg)
25
What we have in healthcare: regional differences
![Page 26: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/26.jpg)
26
Multisided markets pose special challenges…
• Hypothesize about your ecosystem• Hints to solving the ecosystem puzzle: where is the test is performed?
• Think reimbursement• Know your regulators
Value Propositions: One per Customer/ecosystem Segment• Who wants it. Who doesn’t want it?• Clinical Value vs Insurance Value vs Testing Lab Value vs…
![Page 27: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/27.jpg)
Diagnostics and Value Propositions
Comes from Technical Insight Comes from Market Insight
More sensitive
More Efficient
Faster Simpler
Lower cost
Better Bundling
Better Branding
Better Distribution
New test
New user
![Page 28: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/28.jpg)
Examples of Market Insight
Masses of people are more likely to micro-blog than blog
The non-symmetric relationships will allow companies and individuals to self-promote and will impact distribution
European car sharing sensibilities could be adopted in North America
People, particularly in urban environments, no longer wanted to own cars but wanted to have flexibility.
![Page 29: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/29.jpg)
Examples of Market Insight
Need vs Want
![Page 30: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/30.jpg)
30
Why the BMC matters …
1. Value proposition2. Customer segment3. Practice of medicine4. Reimbursement5. Regulatory clearance6. Clinical testing7. OUS markets
(Sure, it does what you want, but not how you wanted it to!)
![Page 31: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/31.jpg)
31
So for next week…
• Customer segments
Which includes (for us)
Reimbursement Regulation
Hypotheses, experiments, results
![Page 32: UCSF Life Sciences Week 1 diagnostics](https://reader036.vdocuments.net/reader036/viewer/2022081516/5590d7121a28ab3a5d8b45d7/html5/thumbnails/32.jpg)
32
For next week
CLINICAL TRIALS
IP
REIM
BURS
EME
NT
ECOSYSTEM?
REGULA
TIO
N